Peregrine Capital Management LLC Sells 41,279 Shares of DexCom, Inc. $DXCM

Posted by George Bondi on Jul 1st, 2026

Peregrine Capital Management LLC trimmed its stake in DexCom, Inc. (NASDAQ:DXCM – Free Report) by 6.3% in the 1st quarter, HoldingsChannel reports. The firm owned 616,540 shares of the medical device company’s stock after selling 41,279 shares during the quarter. DexCom accounts for 1.4% of Peregrine Capital Management LLC’s portfolio, making the stock its 14th biggest position. Peregrine Capital Management LLC’s holdings in DexCom were worth $38,719,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of DXCM. Caliber Wealth Management LLC KS raised its stake in DexCom by 27.8% in the first quarter. Caliber Wealth Management LLC KS now owns 26,900 shares of the medical device company’s stock worth $1,689,000 after buying an additional 5,853 shares in the last quarter. Lansforsakringar Fondforvaltning AB publ boosted its position in DexCom by 32.5% during the 1st quarter. Lansforsakringar Fondforvaltning AB publ now owns 5,458 shares of the medical device company’s stock valued at $343,000 after acquiring an additional 1,340 shares in the last quarter. Apollon Wealth Management LLC grew its holdings in shares of DexCom by 31.2% during the 1st quarter. Apollon Wealth Management LLC now owns 21,420 shares of the medical device company’s stock worth $1,345,000 after acquiring an additional 5,099 shares during the period. Patton Fund Management Inc. purchased a new position in shares of DexCom during the 1st quarter worth approximately $284,000. Finally, Janney Montgomery Scott LLC raised its position in shares of DexCom by 11.7% in the 1st quarter. Janney Montgomery Scott LLC now owns 47,404 shares of the medical device company’s stock worth $2,977,000 after acquiring an additional 4,958 shares in the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

DexCom Stock Performance

Shares of DXCM opened at $67.35 on Wednesday. The company has a quick ratio of 1.64, a current ratio of 1.95 and a debt-to-equity ratio of 0.42. The business’s 50 day moving average price is $67.89 and its 200-day moving average price is $68.12. DexCom, Inc. has a 52 week low of $54.11 and a 52 week high of $89.98. The stock has a market cap of $25.99 billion, a P/E ratio of 28.78, a P/E/G ratio of 1.15 and a beta of 1.45.

DexCom (NASDAQ:DXCM – Get Free Report) last posted its quarterly earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share for the quarter, topping the consensus estimate of $0.47 by $0.09. DexCom had a return on equity of 33.33% and a net margin of 19.31%.The company had revenue of $1.19 billion for the quarter, compared to the consensus estimate of $1.17 billion. During the same quarter in the prior year, the business posted $0.32 EPS. The firm’s quarterly revenue was up 15.0% compared to the same quarter last year. Equities research analysts anticipate that DexCom, Inc. will post 2.57 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. TD Cowen restated a “buy” rating and issued a $95.00 target price (up from $75.00) on shares of DexCom in a research note on Wednesday, June 10th. Deutsche Bank Aktiengesellschaft assumed coverage on DexCom in a report on Tuesday, June 23rd. They issued a “buy” rating and a $86.00 price objective for the company. Bank of America lowered their price objective on DexCom from $100.00 to $80.00 and set a “buy” rating for the company in a research report on Monday, May 18th. Canaccord Genuity Group set a $82.00 target price on shares of DexCom and gave the company a “buy” rating in a report on Monday, May 18th. Finally, Robert W. Baird set a $80.00 target price on shares of DexCom in a research report on Friday, May 1st. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $84.88.

Read Our Latest Stock Analysis on DXCM

Insiders Place Their Bets

In other news, EVP Michael Jon Brown sold 1,700 shares of the stock in a transaction on Monday, June 15th. The stock was sold at an average price of $75.55, for a total value of $128,435.00. Following the sale, the executive vice president directly owned 106,353 shares of the company’s stock, valued at approximately $8,034,969.15. This represents a 1.57% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Jon Coleman sold 4,911 shares of the firm’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $74.13, for a total value of $364,052.43. Following the transaction, the executive vice president owned 95,450 shares of the company’s stock, valued at $7,075,708.50. The trade was a 4.89% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 46,694 shares of company stock valued at $3,343,977. Company insiders own 0.28% of the company’s stock.

DexCom Profile

(Free Report)

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.